Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $130

Benzinga Newsdesk www.benzinga.com Positive 82.2%

Neg 0% Neu 0% Pos 82.2%

Stifel analyst James Condulis maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $125 to $130.